Last week two new papers came out echoing each other about the dangers of bogus “therapies” being offered by predatory stem cell clinics and the risks they pose to patients. The first was from the Pew Charitable Trusts entitled: ‘Harms Linked to Unapproved Stem Cell Interventions Highlight Need for Greater FDA Enforcement’ with a subtitle: … Continue reading Two voices, one message, watch out for predatory stem cell clinics
Vision loss
The Top CIRM Blogs of 2019
This year the most widely read blog was actually one we wrote back in 2018. It’s the transcript of a Facebook Live: “Ask the Stem Cell Team” event about strokes and stroke recovery. Because stroke is the third leading cause of death and disability in the US it’s probably no surprise this blog has lasting … Continue reading The Top CIRM Blogs of 2019
Stem Cell Agency Heads to Inland Empire for Free Patient Advocate Event
I am embarrassed to admit that I have never been to the Inland Empire in California, the area that extends from San Bernardino to Riverside counties. That’s about to change. On Monday, April 16th CIRM is taking a road trip to UC Riverside, and we’re inviting you to join us. We are holding a special, … Continue reading Stem Cell Agency Heads to Inland Empire for Free Patient Advocate Event
Stem Cell Patch Restores Vision in Patients with Age-Related Macular Degeneration
Two UK patients suffering from vision loss caused by age-related macular degeneration (AMD) have regained their sight thanks to a stem cell-based retinal patch developed by researchers from UC Santa Barbara (UCSB). The preliminary results of this promising Phase 1 clinical study were published yesterday in the journal Nature Biotechnology. AMD is one of the … Continue reading Stem Cell Patch Restores Vision in Patients with Age-Related Macular Degeneration
Treatments, cures and clinical trials: an in-person update on CIRM’s progress
Patients and Patient Advocates are at the heart of everything we do at CIRM. That’s why we are holding three free public events in the next few months focused on updating you on the stem cell research we are funding, and our plans for the future. Right now we have 33 projects that we have … Continue reading Treatments, cures and clinical trials: an in-person update on CIRM’s progress
California’s stem cell agency rounds up the year with two more big hits
It’s traditional to end the year with a look back at what you hoped to accomplish and an assessment of what you did. By that standard 2016 has been a pretty good year for us at CIRM. Yesterday our governing Board approved funding for two new clinical trials, one to help kidney transplant patients, the … Continue reading California’s stem cell agency rounds up the year with two more big hits
CIRM-funded stem cell clinical trial for retinitis pigmentosa focuses on next stage
How retinitis pigmentosa erodes normal vision The failure rate for clinical trials is depressingly high. A study from Tufts University in 2010 found that for small molecules – the substances that make up more than 90 percent of the drugs on the market today – the odds of getting from a Phase 1 trial to … Continue reading CIRM-funded stem cell clinical trial for retinitis pigmentosa focuses on next stage
Accelerating the drive for new stem cell treatments
Acceleration is defined as the “increase in the rate or speed of something.” For us that “something” is new stem cell treatments for patients with unmet medical needs. Today our governing Board just approved a $15 million partnership with Quintiles to help us achieve that acceleration. Quintiles was awarded the funding to create a new … Continue reading Accelerating the drive for new stem cell treatments
Cell mate: the man who makes stem cells for clinical trials
When we announced that one of the researchers we fund - Dr. Henry Klassen at the University of California, Irvine - has begun his clinical trial to treat the vision-destroying disease retinitis pigmentosa, we celebrated the excitement felt by the researchers and the hope from people with the disease. But we missed out one group. … Continue reading Cell mate: the man who makes stem cells for clinical trials
Two for 2.0 and Two for us
It began as an ambitious idea; yesterday it became a reality when the CIRM Board approved two projects under CIRM 2.0, one of them a Phase 3 clinical trial for a deadly form of skin cancer. Just to recap, CIRM 2.0 was introduced by Dr. C. Randal Mills when he took over as President and … Continue reading Two for 2.0 and Two for us
The Stem Cellar 